Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026
Korean Team Unveils Breakthrough All-in-One Cancer Nanomedicine
/in Preclinical Research/by MaxIn a groundbreaking advancement for cancer treatment, a team from the Korea Research Institute of Standards and Science (KRISS) has developed an innovative nanomaterial that could transform cancer care. This “all-in-one” nanomedicine, known as gold-iron-gold nanodisks (AuFeAuNDs), integrates diagnosis, treatment, and immune activation into a single platform. Still in pre-clinical stages, this discovery shows significant […]
Early Results of Gedatolisib and Darolutamide in mCRPC Treatment
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMevrometostat Update: a New Phase 3 Trial for mCSPC
/in Clinical Trial, Metastatic, Phase 3/by MaxMDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC
/in Immunotherapy, Preclinical Research/by MaxAlphaGenome: Another Incredible AI Tool for Biology
/in Artificial Intelligence/by MaxPhase 1 Trial of 225Ac-ETN029 for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: WGc-043, Exploring a New mRNA Vaccine for EBV-Positive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Results for Imaging Agent Cu-61 NuriPro Shows Promise for Future Theranostic Option Cu-67
/in Clinical Trial, Metastatic, Phase 1/by MaxAt the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, a promising phase I clinical trial results were presented for Cu-61 NuriPro, a next-generation PET imaging agent specifically designed for patients with PSMA-positive metastatic prostate cancer. This agent targets prostate-specific membrane antigen (PSMA), a protein commonly overexpressed in prostate cancer cells, making […]